Patent Grant
7247313
1. Field of the Invention
This invention is directed to coatings for implantable medical devices, such as drug eluting vascular stents.
2. Description of Related Art
Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
A problem associated with the above procedure includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, a stent is implanted in the lumen to maintain the vascular patency.
Stents are used not only as a mechanical intervention but also as a vehicle for providing biological therapy. As a mechanical intervention, stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically, stents are capable of being compressed, so that they can be inserted through small vessels via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in patent literature disclosing stents which have been applied in PTCA procedures include stents illustrated in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results. One proposed method for medicating stents involves the use of a polymeric carrier coated onto the surface of a stent. A solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer. The embodiments of the invention provide coatings for implantable devices, such as stents, and methods of coating the same.
A coating for an implantable medical device is provided, the coating comprises a thermoplastic polyacrylate material free from acetate species and a therapeutically active agent incorporated therein. The polyacrylate material can include homopolymers, copolymers or terpolymers of alkylacrylates or alkylmethacrylates, and blends thereof. The polyacrylate material can be poly(n-butyl methacrylate). The polyacrylate material can include non-acrylate polymers such as fluorinated polymers or poly(ethylene-co-vinyl alcohol).
According to another embodiment of this invention, a coating for an implantable medical device is provided, the coating comprises a first layer having an active agent incorporated therein and a second layer disposed over the first layer, wherein the second layer comprises a thermoplastic polyacrylate material for modifying the rate of release of the agent.
According to yet another embodiment of the invention, a method of coating an implantable medical device is provided, the method comprises depositing a first layer on the device, the first layer including an active agent for the sustained release of the agent, and depositing a second layer over the first layer, the second layer comprising a thermoplastic polyacrylate material for modifying the rate of release of the agent.
A coating for an implantable medical device, such as a stent, according to one embodiment of the present invention, can include a drug-polymer layer, an optional topcoat layer, and an optional primer layer. The drug-polymer layer can be applied directly onto the stent surface to serve as a reservoir for a therapeutically active agent or drug which is incorporated into the drug-polymer layer. The topcoat layer, which can be essentially free from any therapeutic substances or drugs, serves as a rate limiting membrane which further controls the rate of release of the drug. The optional primer layer can be applied between the stent and the drug-polymer layer to improve the adhesion of the drug-polymer layer to the stent.
According to one embodiment of the present invention, polymers of esters having the general formula (I)
—[CH2—C(X)(COOR)]m—[CH2—C(X′)(COOR′)]n—[CH2—C(X″) (COOR″)]p—, (I)
or blends thereof, can be used for making the stent coatings.
In formula (I), X, X′, and X″ is each, independently, a hydrogen atom (acrylates) or an alkyl group, such as a methyl group CH3 (methacrylates); R, R′ and R″ is each, independently, a C1 to C12 straight chained or branched aliphatic radical; “m” is an integer larger than 1, and “n” and “p” is each 0 or an integer. If both n=0 and p=0, the polymer of formula (I) is a homopolymer (i.e., PBMA). If n≠10 and p=0, or n=0 and p≠0, the polymer of formula (I) is a copolymer, and if n≠0 and p≠0, the polymer of formula (I) is a terpolymer.
Polymers of formula (I) can be used for making either the drug-polymer layer, the topcoat membrane, the optional primer layer, or any combination thereof. For the purposes of the present invention, such polymers, or blends thereof, are defined as “polyacrylates” or as “polyacrylate materials.”
One example of a polyacrylate suitable for fabricating either the drug-polymer layer or the topcoat membrane is poly(n-butyl methacrylate) (PBMA), described by formula (I) where X=CH3, n=0, p=0, and “R” is a n-butyl radical C4H9 (—CH2—CH2—CH2—CH3). PBMA has good biocompatibility, is soluble in many common solvents, has good mechanical and physical properties, and adheres well to the underlying stent surface or the primer layer. PBMA is available commercially from Aldrich Chemical Co. of Milwaukee, Wis., and from Esschem, Inc. of Lynwood, Pa.
The rate of release of the drug through the polymer, such as the topcoat membrane, is related to the rate of diffusion of the drug through the matrix. The slower the rate of diffusion, the greater the polymer's ability to prolong the rate of release and the residence time of the drug at the implantation site. The rate of diffusion is in turn related to the water adsorption rate, the degree of crystallinity, if any, and the glass transition temperature (Tg) of the polymer.
As a general rule, the more water the polymer absorbs at body temperature, the faster the drug diffuses out of the polymer, and the greater the degree of crystallinity in the polymer's structure, the slower a drug will diffuse out of the polymer. Since all of the R, R′ and R″ groups in these polyacrylates are aliphatic, water adsorption tends to be low. One common technique for producing these polymers is by free radical polymerization yielding amorphous polymers with no crystallinity. Hence, it is the glass transition temperature that is one of the important discriminating characteristic for these polymers.
Consequently, the present invention allows manipulating the rate of release of the drug into the blood stream by varying Tg of the polymer or the blend of polymers forming the drug-polymer layer and/or the membrane. Typically, it is desirable to decrease the rate of release. In order to do so, the polyacrylates having higher values of Tg can be used. Examples of such polyacrylates include poly(methyl methacrylate) (Tg=105° C.) and poly(tert-butyl methacrylate) (Tg=107° C.).
However, if it is desirable to increase the rate of release, the polyacrylates having low values of Tg can be used. PBMA is one of such polyacrylates having the Tg of about 20° C. Examples of other suitable polyacrylates having low Tg include poly(n-hexyl methacrylate) (Tg=−5° C.) and poly(methyl acrylate) (Tg=9° C.).
For a copolymer of these polyacrylates, the Tg (on the Kelvin scale) is generally the mass-fraction weighted average of the constituent components of the copolymer. Consequently, a copolymer or terpolymer of formula (I) with predetermined higher or lower value of Tg can be used as a drug-polymer layer and/or a topcoat membrane, thus providing a desirable lower or higher rate of release of the drug, respectively. For example, a random poly(methyl methacrylate-co-n-butyl methacrylate) [P(MMA-BMA)], having about 30 molar percent of methyl-methacrylate-derived units and about 70 molar percent of n-butyl-methacrylate-derived units, has a theoretical Tg of about 45.50° C. Therefore, a topcoat membrane made of P(MMA-BMA) will provide faster drug release than pure PMMA but slower than pure PBMA. Similarly, blends of individual polyacrylates, e.g., PBMA and PMMA can be used.
Some examples of polyacrylates that are suitable for fabrication of the coating, e.g., the drug-polymer layer and/or the topcoat membrane, are summarized in Table 1.
Only homo- and copolymers are listed in Table 1 (that is, the polymers of formula (I) where p=0), but it should be understood that terpolymers corresponding to formula (I) (when n≠0 and p≠0) can be used as well.
To fabricate the coating, one of the polyacrylates, or a blend thereof can be applied on the stent using commonly used techniques known to those having ordinary skill in the art. For example, the polyacrylate can be applied to the stent by dissolving the polymer in a solvent, or a mixture of solvents, and applying the resulting solution on the stent by spraying or immersing the stent in the solution.
Representative examples of some suitable solvents include N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF), tethrahydrofurane (THF), cyclohexanone, xylene, toluene, acetone, methyl ethyl ketone, propylene glycol monomethyl ether, methyl butyl ketone, ethyl acetate, n-butylacetate, and dioxane. Examples of suitable mixtures of solvents include mixtures of DMAC and methanol (e.g., a 50:50 by mass mixture), cyclohexanone and acetone (e.g., 80:20, 50:50, 20:80 by mass mixtures), acetone and xylene (e.g. a 50:50 by mass mixture), and acetone, FLUX REMOVER AMS, and xylene (e.g., a 10:50:40 by mass mixture). FLUX REMOVER AMS is trade name of a solvent manufactured by Tech Spray, Inc. of Amarillo, Tex. comprising about 93.7% of a mixture of 3,3-dichloro-1,1,1,2,2-pentafluoropropane and 1,3-dichloro-1,1,2,2,3-pentafluoropropane, and the balance methanol, with trace amounts of nitromethane.
In addition, blends of polyacrylates with polymers other than polyacrylates can be used to fabricate the coating. In one embodiment, the blend of polyacrylates with non-acrylate materials is free from acetate species. Poly(ethylene-co-vinyl alcohol) (EVAL) is one example of a suitable non-acrylate polymer. EVAL has the general formula —[CH2—CH2]q—[CH2—CH(OH)]r—, where “q” and “r” is each an integer. EVAL may also include up to 5 molar % of units derived from styrene, propylene and other suitable unsaturated monomers. A brand of copolymer of ethylene and vinyl alcohol distributed commercially under the trade name EVAL by Aldrich Chemical Co., or manufactured by EVAL Company of America of Lisle, Ill., can be used.
Examples of other polymers with which polyacrylates can be blended include fluorinated polymers, such as poly(vinylidene fluoride) (PVDF) and poly(vinylidene fluoride-co-hexafluoro propene) (PVDF-HFP). The blend of a polyacrylate and a fluorinated polymer can contain between about 10 and about 95% (mass) of the fluorinated polymer.
The polyacrylates can be used to manufacture the primer layer, drug-polymer layer, topcoat membrane, or all three layers. For example, the polyacrylates can be used to make both the drug-polymer layer and the topcoat membrane, but not the primer layer. Any combination of the three layers can include a polyacrylate, so long as at least one of the layers includes the material. If a polyacrylate is used to make only one of the layers, the other layer or layers can be made of an alternative polymer.
Representative examples of suitable alternative polymers include EVAL, poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane; poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), co-poly(ether-esters) (e.g. PEO/PLA), polyalkylene oxalates, polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers other than polyacrylates, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene fluoride and polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers), polyamides (such as Nylon 66 and polycaprolactam), alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose.
The coating of the present invention has been described in conjunction with a stent. However, the coating can also be used with a variety of other medical devices. Examples of the implantable medical device, that can be used in conjunction with the embodiments of this invention include stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, axius coronary shunts and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt-chromium alloys (e.g., ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, tantalum-based alloys, nickel-titanium alloy, platinum, platinum-based alloys such as, e.g., platinum-iridium alloy, iridium, gold, magnesium, titanium, titanium-based alloys, zirconium-based alloys, or combinations thereof. Devices made from bioabsorbable or biostable polymers can also be used with the embodiments of the present invention.
“MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
The active agent or the drug can include any substance capable of exerting a therapeutic or prophylactic effect for a patient. The drug may include small molecule drugs, peptides, proteins, oligonucleotides, and the like. The active agent could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis. Examples of drugs include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof. Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin, hydrochloride, and mitomycin. Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin. Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopril, calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (ω-3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon; genetically engineered epithelial cells; rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of Everolimus available from Novartis) 40-O-(3-hydroxy)propyl-rapamycin and 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin; tacrolimus; and dexamethasone.
Some embodiments of the present invention are illustrated by the following Examples.
A polymer solution containing between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of EVAL and the balance, DMAC solvent, can be prepared. The solution can be applied onto a stent to form a primer layer. To apply the primer layer, a spray apparatus, such as an EFD 780S spray nozzle with a VALVEMATE 7040 control system, manufactured by EFD, Inc. of East Providence, R.I. can be used. The EFD 780S spray nozzle is an air-assisted external mixing atomizer. The composition is atomized by air and applied to the stent surfaces. During the process of applying the composition, the stent can be optionally rotated about its longitudinal axis, at a speed of 50 to about 150 rpm. The stent can also be linearly moved along the same axis during the application.
The EVAL solution can be applied to a 13-mm TETRA stent (available from Guidant Corporation) in a series of 10-second passes, to deposit, for example, 10 μg of coating per spray pass. Instead of the 13-mm TETRA stent, another suitable stent can be used, for example, a 12-mm VISION stent (also available from Guidant Corporation). Between the spray passes, the stent can be dried for about 10 seconds using flowing air with a temperature of about 60° C. Five spray passes can be applied, followed by baking the primer layer at about 140° C. for one hour. As a result, a primer layer can be formed having a solids content of about 50 μg. “Solids” means the amount of the dry residue deposited on the stent after all volatile organic compounds (e.g., the solvent) have been removed.
A drug-containing formulation can be prepared comprising:
(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of EVAL;
(b) between about 0.1 mass % and about 2 mass %, for example, about 1.0 mass % of an active agent, for example, Everolimus; and
(c) the balance, a solvent mixture of DMAC and pentane, the solvent mixture containing about 80 (mass) % of DMAC and about 20 (mass) % of pentane.
In a manner identical to the application of the primer layer, five spray passes can be performed, followed by baking the drug-polymer layer at about 50° C. for about 2 hours, to form the drug-polymer layer having a solids content between about 30 μg and 750 μg, for example, about 90 μg, and a drug content of between about 10 μg and about 250 μg, for example, 30 μg.
Finally, a topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % PBMA and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS, and xylene. In a manner identical to the application of the primer layer and the drug-polymer layer, a number of spray passes are performed followed by final baking at about 50° C. for about 2 hours. As a result, the topcoat membrane can be formed, the membrane having a solids content of between about 30 μg and about 350 μg, for example, about 50 μg.
A stent was coated as described in Example 1, except instead of the Everolimus, estradiol was used. The coated stent was tested for a study of the drug release. The stent was immersed for 24 hours in bovine serum. The drug was extracted, and the amount of estradiol released after 24 hours was measured chromatographically (by HPLC). The results of this study are summarized in Table 2.
Further, a kinetic study of the drug release profile was conducted. The stent had the total amount of solids of the topcoat membrane of about 160 μg and the total amount of estradiol in the drug-polymer layer of about 30 μg. The stent was immersed in a phosphate buffered saline solution having 1 mass % of sodium dodecyl sulfate. A sample of the solution was taken every 20 minutes and analyzed by HPLC for the amount of estradiol released.
As seen from the release profile for three different coated stents shown on
A stent was coated as described in Example 1, except instead of Everolimus, etoposide was used. The coated stent was tested for a study of the drug release as described in Example 2. The results of this study are summarized in Table 3.
A kinetic study of the drug release profile was conducted. The stent was immersed in a phosphate-buffered saline solution having about 1 mass % of sodium dodecyl sulfate. The solution was frequently sampled and the drug concentration was measured using HPLC. The stent had the total amount of solids of the topcoat membrane of about 30 μg and the total amount of estradiol in the drug-polymer layer of about 160 μg. As seen from the release profile for three different coated stents shown on
A primer layer can be applied onto a stent as described in Example 1. A drug formulation can be prepared comprising:
(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of PBMA;
(b) between about 0.1 mass % and about 2 mass %, for example, about 1.6 mass % of a therapeutically active substance, for example, everolimus; and
(c) the balance, a solvent system, for example a 60:40 (mass) blend of acetone and xylene.
The drug containing formulation can then be applied to the stent, and a drug-polymer layer is formed, in a manner identical to that described in Example 1. The solids contents of the drug-polymer layer can be 1,200 μg.
Finally, a topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % PBMA and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene, and the topcoat membrane can be formed, in a manner identical to that described in Example 1. The topcoat membrane can have a solids content of between about 20 μg and about 200 μg, for example, about 30 μg.
A primer layer can be applied onto a 8-mm stent as described in Example 1. A drug formulation can be prepared comprising:
(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of PBMA;
(b) between about 0.1 mass % and about 2 mass %, for example, about 1.6 mass % of a therapeutically active substance, for example, Everolimus; and
(c) the balance, a solvent system, for example a 60:40 (mass) blend of acetone and xylene.
The drug formulation can then be applied onto the stent, and a drug-polymer layer is formed in a manner identical to that described in Example 1. The solids contents of the drug-polymer layer can be 1,200 μg. In this Example, the stent coating has no separate topcoat membrane.
A primer layer can be applied onto a 8-mm stent as described in Example 1. A drug formulation can be prepared comprising:
(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of P(MMA-BMA) having a weight-average molecular weight Mw of about 150,000 available from Aldrich Chemical Company under the name PBM 150;
(b) between about 0.1 mass % and about 2 mass %, for example, about 1.0 mass % of an active agent, for example, Everolimus; and
(c) the balance, a solvent system, for example a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene.
PBM 150 contains about 79.2 mass % of units derived from BMA. The drug formulation can then be applied onto the dried primer layer, and a drug-polymer layer is formed, in a manner identical to that described in Example 1. The drug-polymer layer can have the total amount of solids of between about 300 and 600 μg, for example, about 520 μg. In this Example, the stent coating has no separate topcoat membrane.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 1, the drug-polymer layer having the total amount of EVAL between about 300 and 800 μg, for example, about 325 μg. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % P(MMA-BMA) having about 66.5 mass % of units derived from BMA, and the balance of a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The topcoat membrane can be formed having the total amount of solids between about 20 and 200 μg, for example, about 30 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 1, the drug-polymer layer having the total amount of EVAL between about 300 and 800 μg, for example, about 380 μg. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 1:1 (by mass) blend of P(MMA-BMA) and PBMA, and the balance of a solvent system, for example, the solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The P(MMA-BMA)/PBMA blend can have about 83.3 mass % of units derived from BMA. The topcoat membrane can be formed having the total amount of solids between about 20 and 200 μg, for example, about 30 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 1, the drug-polymer layer having the total amount of EVAL between about 300 and 800 μg, for example, about 350 μg. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 2:1 (by mass) blend of P(MMA-BMA) and PBMA, and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The P(MMA-BMA)/PBMA blend can have about 77.8 mass % of units derived from BMA. The topcoat membrane can have a total amount of solids between about 20 and 200 μg, for example, about 28 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 9. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 4:1 (by mass) blend of P(MMA-BMA) and PBMA, and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The P(MMA-BMA)/PBMA blend can have about 73.3 mass % of units derived from BMA. The topcoat membrane can have a total amount of solids between about 20 and 200 μg, for example, about 32 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 9. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of PEMA, and the balance a solvent system, for example, a solvent system including a 80:20 (mass) blend of acetone and cyclohexanone. Poly(ethyl methacrylate) having a weight-average molecular weight Mw of about 101,400 available from Aldrich Chemical Company is one example of a brand of PEMA that can be used. In a manner identical to the application of the primer layer and the drug-polymer layer, the topcoat composition can be applied onto the dried drug-polymer layer. A number of spray passes can be performed followed by final baking, first at about 60° C. for about 2 hours and then at about 140° C. for about 1 hour. The topcoat membrane can be formed, the membrane having a solids content of between about 20 μg and about 300 μg, for example, about 40 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 9. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a blend of PEMA with a fluorinated polymer; and the balance a solvent system, for example, a solvent system including a 50:50 (mass) blend of acetone and cyclohexanone. The brand of PEMA described in Example 10 can be used. One example of the fluorinated polymer that can be used in a blend with PEMA is PVDF-HFP, such as SOLEF 21508 having about 85 mass % of vinylidene fluoride-derived units and about 15 mass % of hexafluoro propene-derived units. SOLEF 21508 is available from Solvay Fluoropolymers, Inc. of Houston, Tex. The PEMA/SOLEF 21508 blend can be 3:1 (mass) (containing about 75 mass % of PEMA and about 25 mass % of SOLEF 21508). In a manner identical to the application of the primer layer and the drug-polymer layer, the topcoat composition can be applied onto the dried drug-polymer layer. A number of spray passes can be performed followed by final baking, first at about 60° C. for about 2 hours and then at about 100° C. for about 1 hour. The topcoat membrane can have a solids content of between about 20 μg and about 300 μg, for example, about 42 μg.
A stent was coated as described in Example 12, except instead of the 3:1 PEMA/SOLEF 21508 blend, a 3:1 (mass) blend of PEMA/PBMA can be used to form the topcoat membrane. The dry topcoat membrane can have a solids content of between about 20 μg and about 300 μg, for example, about 50 μg.
A stent was coated as described in Example 13, except instead of the 3:1 PEMA/PBMA blend, a 1:1 (mass) blend of PEMA/PBMA can be used to form the topcoat membrane (containing about 50 mass % of PEMA and about 50 mass % of PBMA).
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 4. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 1:1 (by mass) blend of PBMA and EVAL, and the balance a solvent system, for example, a solvent system including a 80:20 (mass) blend of DMAC and pentane. The topcoat membrane can have a total amount of solids of between about 20 and 200 μg, for example, about 30 μg.
A primer layer can be applied onto a stent as described in Example 1. A drug formulation can be prepared comprising:
(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 1:1 (by mass) blend of PBMA and EVAL;
(b) between about 0.1 mass % and about 2 mass %, for example, about 1.6 mass % of a therapeutically active substance, for example, Everolimus; and
(c) the balance, a solvent system, for example, a solvent system which includes a 80:20 (mass) blend of DMAC and pentane.
The drug containing formulation can then be applied onto the stent. The solids contents of the drug-polymer layer can be 1,200 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 16. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % PBMA and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The topcoat membrane can have a solids content of between about 20 μg and about 200 μg, for example, about 30 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 16. A topcoat composition to control the drug release rate can be prepared as described in Example 15. The topcoat membrane can have a total amount of solids between about 20 and 200 μg, for example, about 30 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 1. A topcoat composition to control the drug release rate can be prepared as described in Example 15. The topcoat membrane can be formed, in a manner identical to that described in Example 1, the topcoat membrane having the total amount of solids between about 20 and 200 μg, for example, about 30 μg.
A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 16. A topcoat composition to control the drug release rate can be prepared, the composition comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % EVAL and the balance DMAC solvent The topcoat membrane can be formed, in a manner identical to that described in Example 1.
The information discussed in Examples 1-20 is summarized in Table 4.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
This is a continuation-in-part of U.S. patent application Ser. No. 09/894,293, filed on Jun. 27, 2001, now abandoned.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2968649 | Pailthorp et al. | Jan 1961 | A |
| 3051677 | Rexford | Aug 1962 | A |
| 3178399 | Lo | Apr 1965 | A |
| 3324069 | Koblitz et al. | Jun 1967 | A |
| 3779805 | Alsberg | Dec 1973 | A |
| 3856827 | Cavitt | Dec 1974 | A |
| 4076929 | Dohany | Feb 1978 | A |
| 4197380 | Chao et al. | Apr 1980 | A |
| 4304010 | Mano | Dec 1981 | A |
| 4346710 | Thanawalla et al. | Aug 1982 | A |
| 4353960 | Endo et al. | Oct 1982 | A |
| 4399264 | Squire | Aug 1983 | A |
| 4413359 | Akiyama et al. | Nov 1983 | A |
| 4423183 | Close | Dec 1983 | A |
| 4485250 | Squire | Nov 1984 | A |
| 4530569 | Squire | Jul 1985 | A |
| 4564013 | Lilenfeld et al. | Jan 1986 | A |
| 4569978 | Barber | Feb 1986 | A |
| 4632842 | Karwoski et al. | Dec 1986 | A |
| 4636346 | Gold et al. | Jan 1987 | A |
| 4718907 | Karwoski et al. | Jan 1988 | A |
| 4733665 | Palmaz | Mar 1988 | A |
| 4749585 | Greco et al. | Jun 1988 | A |
| 4754009 | Squire | Jun 1988 | A |
| 4770939 | Sietsess et al. | Sep 1988 | A |
| 4800882 | Gianturco | Jan 1989 | A |
| 4871357 | Hsu et al. | Oct 1989 | A |
| 4876109 | Mayer et al. | Oct 1989 | A |
| 4886062 | Wiktor | Dec 1989 | A |
| 4897457 | Nakamura et al. | Jan 1990 | A |
| 4908404 | Benedict et al. | Mar 1990 | A |
| 4910276 | Nakamura et al. | Mar 1990 | A |
| 4931287 | Bae et al. | Jun 1990 | A |
| 4935477 | Squire | Jun 1990 | A |
| 4948851 | Squire | Aug 1990 | A |
| 4973142 | Squire | Nov 1990 | A |
| 4975505 | Squire | Dec 1990 | A |
| 4977008 | Squire | Dec 1990 | A |
| 4977025 | Squire | Dec 1990 | A |
| 4977026 | Squire | Dec 1990 | A |
| 4977297 | Squire | Dec 1990 | A |
| 4977901 | Ofstead | Dec 1990 | A |
| 4982056 | Squire | Jan 1991 | A |
| 4985308 | Squire | Jan 1991 | A |
| 4999248 | Squire | Mar 1991 | A |
| 5000547 | Squire | Mar 1991 | A |
| 5006382 | Squire | Apr 1991 | A |
| 5030394 | Sietses et al. | Jul 1991 | A |
| 5047020 | Hsu | Sep 1991 | A |
| 5051114 | Nemser et al. | Sep 1991 | A |
| 5051978 | Mayer et al. | Sep 1991 | A |
| 5053048 | Pinchuk | Oct 1991 | A |
| 5076659 | Bekiarian et al. | Dec 1991 | A |
| 5093427 | Barber | Mar 1992 | A |
| 5107852 | Davidson et al. | Apr 1992 | A |
| 5110645 | Matsumoto et al. | May 1992 | A |
| 5112457 | Marchant | May 1992 | A |
| 5176972 | Bloom et al. | Jan 1993 | A |
| 5185408 | Tang et al. | Feb 1993 | A |
| 5246451 | Trescony et al. | Sep 1993 | A |
| 5276121 | Resnick | Jan 1994 | A |
| 5296283 | Froggatt | Mar 1994 | A |
| 5302385 | Khan et al. | Apr 1994 | A |
| 5308685 | Froggatt | May 1994 | A |
| 5310838 | Hung et al. | May 1994 | A |
| 5324889 | Resnick | Jun 1994 | A |
| 5326839 | Resnick | Jul 1994 | A |
| 5328471 | Slepian | Jul 1994 | A |
| 5336518 | Narayanan et al. | Aug 1994 | A |
| 5338608 | Resnick | Aug 1994 | A |
| 5342348 | Kaplan | Aug 1994 | A |
| 5353368 | Resnick | Oct 1994 | A |
| 5354910 | Hung et al. | Oct 1994 | A |
| 5368566 | Crocker | Nov 1994 | A |
| 5380299 | Fearnot et al. | Jan 1995 | A |
| 5383853 | Jung et al. | Jan 1995 | A |
| 5383928 | Scott et al. | Jan 1995 | A |
| 5395311 | Andrews | Mar 1995 | A |
| 5403341 | Solar | Apr 1995 | A |
| 5408020 | Hung et al. | Apr 1995 | A |
| 5417969 | Hsu et al. | May 1995 | A |
| 5443458 | Eury | Aug 1995 | A |
| 5447724 | Helmus et al. | Sep 1995 | A |
| 5455040 | Marchant | Oct 1995 | A |
| 5464650 | Berg et al. | Nov 1995 | A |
| 5545208 | Wolff et al. | Aug 1996 | A |
| 5560463 | Link et al. | Oct 1996 | A |
| 5562734 | King | Oct 1996 | A |
| 5569463 | Helmus et al. | Oct 1996 | A |
| 5575818 | Pinchuk | Nov 1996 | A |
| 5578073 | Haimovich et al. | Nov 1996 | A |
| 5584877 | Miyake et al. | Dec 1996 | A |
| 5591224 | Schwartz et al. | Jan 1997 | A |
| 5604283 | Wada et al. | Feb 1997 | A |
| 5605696 | Eury et al. | Feb 1997 | A |
| 5616608 | Kinsella et al. | Apr 1997 | A |
| 5628728 | Tachibana et al. | May 1997 | A |
| 5632771 | Boatman et al. | May 1997 | A |
| 5632776 | Kurumatani et al. | May 1997 | A |
| 5632840 | Campbell | May 1997 | A |
| 5635201 | Fabo | Jun 1997 | A |
| 5667767 | Greff et al. | Sep 1997 | A |
| 5670558 | Onishi et al. | Sep 1997 | A |
| 5679400 | Tuch | Oct 1997 | A |
| 5684061 | Ohnishi et al. | Nov 1997 | A |
| 5691311 | Maraganore et al. | Nov 1997 | A |
| 5697967 | Dinh et al. | Dec 1997 | A |
| 5700286 | Tartaglia et al. | Dec 1997 | A |
| 5713949 | Jayaraman | Feb 1998 | A |
| 5716981 | Hunter et al. | Feb 1998 | A |
| 5750234 | Johnson et al. | May 1998 | A |
| 5758205 | Hara et al. | May 1998 | A |
| 5759205 | Valentini | Jun 1998 | A |
| 5760118 | Sinclair et al. | Jun 1998 | A |
| 5776184 | Tuch | Jul 1998 | A |
| 5804318 | Pinchuk et al. | Sep 1998 | A |
| 5820917 | Tuch | Oct 1998 | A |
| 5824048 | Tuch | Oct 1998 | A |
| 5824049 | Ragheb et al. | Oct 1998 | A |
| 5827587 | Fukushi | Oct 1998 | A |
| 5830178 | Jones et al. | Nov 1998 | A |
| 5837008 | Berg et al. | Nov 1998 | A |
| 5837313 | Ding et al. | Nov 1998 | A |
| 5851508 | Greff et al. | Dec 1998 | A |
| 5858746 | Hubbell et al. | Jan 1999 | A |
| 5858990 | Walsh | Jan 1999 | A |
| 5860963 | Azam et al. | Jan 1999 | A |
| 5861168 | Cooke et al. | Jan 1999 | A |
| 5865814 | Tuch | Feb 1999 | A |
| 5869127 | Zhong | Feb 1999 | A |
| 5873904 | Ragheb et al. | Feb 1999 | A |
| 5874165 | Drumheller | Feb 1999 | A |
| 5879697 | Ding et al. | Mar 1999 | A |
| 5897911 | Loeffer | Apr 1999 | A |
| 5900425 | Kanikanti et al. | May 1999 | A |
| 5911704 | Humes | Jun 1999 | A |
| 5921933 | Sarkis et al. | Jul 1999 | A |
| 5922393 | Jayaraman | Jul 1999 | A |
| 5928279 | Shannon et al. | Jul 1999 | A |
| 5932299 | Katoot | Aug 1999 | A |
| 5945115 | Dunn et al. | Aug 1999 | A |
| 5971954 | Conway et al. | Oct 1999 | A |
| 5980928 | Terry | Nov 1999 | A |
| 5980972 | Ding | Nov 1999 | A |
| 5997517 | Whitbourne | Dec 1999 | A |
| 6015541 | Greff et al. | Jan 2000 | A |
| 6033724 | Molitor | Mar 2000 | A |
| 6042875 | Ding et al. | Mar 2000 | A |
| 6051648 | Rhee et al. | Apr 2000 | A |
| 6056993 | Leidner et al. | May 2000 | A |
| 6060451 | DiMaio et al. | May 2000 | A |
| 6060534 | Ronan et al. | May 2000 | A |
| 6080488 | Hostettler et al. | Jun 2000 | A |
| 6090134 | Tu et al. | Jul 2000 | A |
| 6096070 | Ragheb et al. | Aug 2000 | A |
| 6096396 | Patton et al. | Aug 2000 | A |
| 6096798 | Luthra et al. | Aug 2000 | A |
| 6096809 | Lorcks et al. | Aug 2000 | A |
| 6099562 | Ding et al. | Aug 2000 | A |
| 6099563 | Zhong | Aug 2000 | A |
| 6110188 | Narciso, Jr. | Aug 2000 | A |
| 6110483 | Whitbourne et al. | Aug 2000 | A |
| 6113629 | Ken | Sep 2000 | A |
| 6120536 | Ding et al. | Sep 2000 | A |
| 6120904 | Hostettler et al. | Sep 2000 | A |
| 6121027 | Clapper et al. | Sep 2000 | A |
| 6124045 | Soda et al. | Sep 2000 | A |
| 6129761 | Hubbell | Oct 2000 | A |
| 6153252 | Hossainy et al. | Nov 2000 | A |
| 6165212 | Dereume et al. | Dec 2000 | A |
| 6179817 | Zhong | Jan 2001 | B1 |
| 6197051 | Zhong | Mar 2001 | B1 |
| 6203551 | Wu | Mar 2001 | B1 |
| 6214901 | Chudzik et al. | Apr 2001 | B1 |
| 6224894 | Jamiolkowski et al. | May 2001 | B1 |
| 6231590 | Slaikeu et al. | May 2001 | B1 |
| 6242041 | Katoot et al. | Jun 2001 | B1 |
| 6254632 | Wu et al. | Jul 2001 | B1 |
| 6258121 | Yang et al. | Jul 2001 | B1 |
| 6262034 | Mathiowitz et al. | Jul 2001 | B1 |
| 6273913 | Wright et al. | Aug 2001 | B1 |
| 6299604 | Ragheb et al. | Oct 2001 | B1 |
| 6319520 | Wuthrich et al. | Nov 2001 | B1 |
| 6344035 | Chudzik et al. | Feb 2002 | B1 |
| 6362271 | Lin et al. | Mar 2002 | B1 |
| 6408878 | Unger et al. | Jun 2002 | B2 |
| 6410612 | Hatanaka | Jun 2002 | B1 |
| 6464683 | Samuelson et al. | Oct 2002 | B1 |
| 6503556 | Harish et al. | Jan 2003 | B2 |
| 6545097 | Pinchuk et al. | Apr 2003 | B2 |
| 6551708 | Tsuda et al. | Apr 2003 | B2 |
| 6716444 | Castro et al. | Apr 2004 | B1 |
| 6746773 | Llanos et al. | Jun 2004 | B2 |
| 6939376 | Shulze et al. | Sep 2005 | B2 |
| 20010014717 | Hossainy et al. | Aug 2001 | A1 |
| 20010029351 | Falotico et al. | Oct 2001 | A1 |
| 20020051730 | Bodnar et al. | May 2002 | A1 |
| 20020090389 | Humes et al. | Jul 2002 | A1 |
| 20020094440 | Llanos et al. | Jul 2002 | A1 |
| 20020099438 | Furst | Jul 2002 | A1 |
| 20020111590 | Davila et al. | Aug 2002 | A1 |
| 20020122877 | Harish et al. | Sep 2002 | A1 |
| 20020123801 | Pacetti et al. | Sep 2002 | A1 |
| 20020133183 | Lentz et al. | Sep 2002 | A1 |
| 20020143386 | Davila et al. | Oct 2002 | A1 |
| 20020165608 | Llanos et al. | Nov 2002 | A1 |
| 20020188037 | Chudzik et al. | Dec 2002 | A1 |
| 20030004563 | Jackson et al. | Jan 2003 | A1 |
| 20030031780 | Chudzik et al. | Feb 2003 | A1 |
| 20030039689 | Chen et al. | Feb 2003 | A1 |
| 20030060877 | Falotico et al. | Mar 2003 | A1 |
| 20030065346 | Evens et al. | Apr 2003 | A1 |
| 20030065377 | Davila et al. | Apr 2003 | A1 |
| 20030073961 | Happ | Apr 2003 | A1 |
| 20030077312 | Schmulewicz et al. | Apr 2003 | A1 |
| 20040102758 | Davila et al. | May 2004 | A1 |
| Number | Date | Country |
|---|---|---|
| 19723723 | Dec 1998 | DE |
| 0568310 | Nov 1993 | EP |
| 0623354 | Nov 1994 | EP |
| 0633032 | Jan 1995 | EP |
| 0 665 023 | Aug 1995 | EP |
| 0747069 | Dec 1996 | EP |
| 0815803 | Jan 1998 | EP |
| 0893108 | Jan 1999 | EP |
| 0950385 | Oct 1999 | EP |
| 0950386 | Oct 1999 | EP |
| 0 970 711 | Jan 2000 | EP |
| 0968688 | Jan 2000 | EP |
| 0997115 | May 2000 | EP |
| 1 023 879 | Aug 2000 | EP |
| 1 192 957 | Apr 2002 | EP |
| WO 9205695 | Apr 1992 | WO |
| WO 9218320 | Oct 1992 | WO |
| WO 9402185 | Feb 1994 | WO |
| WO 9621404 | Jul 1996 | WO |
| WO 9741164 | Nov 1997 | WO |
| WO 9808463 | Mar 1998 | WO |
| WO 9813405 | Apr 1998 | WO |
| WO 9836784 | Aug 1998 | WO |
| WO 9858680 | Dec 1998 | WO |
| WO 9932051 | Jul 1999 | WO |
| WO 9955396 | Nov 1999 | WO |
| WO 0002599 | Jan 2000 | WO |
| WO 0012147 | Mar 2000 | WO |
| WO 0027455 | May 2000 | WO |
| WO 0029043 | May 2000 | WO |
| WO 0032255 | Jun 2000 | WO |
| WO 0038754 | Jul 2000 | WO |
| WO 0041738 | Jul 2000 | WO |
| WO 0064506 | Nov 2000 | WO |
| WO 0101890 | Jan 2001 | WO |
| WO 0130403 | May 2001 | WO |
| WO 0149340 | Jul 2001 | WO |
| WO 0187342 | Nov 2001 | WO |
| WO 0187368 | Nov 2001 | WO |
| WO 0187372 | Nov 2001 | WO |
| WO 0187376 | Nov 2001 | WO |
| WO 0224249 | Mar 2002 | WO |
| WO 0226139 | Apr 2002 | WO |
| WO 0226271 | Apr 2002 | WO |
| WO 0226281 | Apr 2002 | WO |
| WO 0247732 | Jun 2002 | WO |
| WO 03022324 | Mar 2003 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20050106203 A1 | May 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09894293 | Jun 2001 | US |
| Child | 10176504 | US |
